Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenzilumab,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Humanigen
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, PCI will purchase Humaneered (lenzilumab), for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
Brand Name : Humaneered
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 16, 2022
Lead Product(s) : Lenzilumab,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Humanigen
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
